These results indicate that lenvatinib might be more effective in suppressing tumor progression in younger patients with high AFP levels, and sorafenib and post-sorafenib anti-HCC treatment might be more effective in the elderly with low AFP levels and small tumor size. The gene discussed is AFP; the disease is hepatocellular carcinoma.